...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!

I don't know anything about Dr Thompson but the aspect that I like is..."He has taken companies public on the TSX, NASDAQ and former Alberta Stock Exchange, as well as led successful cross-listings (from the TSX to the NASDAQ)."

Any business skill that he can bring to the board and company is welcome from my perspective. I've become quite dissillusioned by the lack of business skills at both companies and it's about time that these companies get down to business.

Perhaps this appointment is a hint that shareholder liquidity is in the works?

GLTA

Toinv

Share
New Message
Please login to post a reply